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DOI 10.1016/j.chembiol.2010.11.006Alzheimer’s disease (AD), Parkinson’s
disease (PD), cystic fibrosis (CF): all devas-
tating diseases with virtually no effective
treatments. While some companies are
digging deeper into the genetic bases for
these diseases, one Cambridge, MA,
based company is going the other way.
Rather than spiraling the research micro-
scope down into ever smaller layers of
biology, Proteostasis Therapeutics, Inc.,
(PTI) is taking amacro view. They are inter-
rogating the biological causes of diseases
by assessing the overall functionality of
proteins in relation to their environments,
a concept known as protein homeostasis.
The history of protein research in large
pharma and biotech has mostly been
focused on a target protein including
enzymes and antibodies. ‘‘But if you think
about that space of biology between the‘‘If you do not embrace the system, you are unlikely to be
successful.’’ —Jeffery Kellybirth of a protein and the final fully folded,
fully assembled functional protein, all of
that biology in between is really the remit
of proteostasis,’’ explains Peter Reinhart,
Ph.D., PTI’s CEO.
Targeting 10–12 Key Cellular
Pathways
PTI is interested in cellular pathways and
mechanisms involved in maintaining
protein homeostasis. ‘‘We are interested
in what allows proteins to fold properly,
the cellular processes that get rid of mis-
folded proteins, and the protein degrada-
tion pathways that recognize when things
are not right and degrade them,’’ explains
Reinhart, who remains an associate
professor of neuroscience at Duke
Medical Center. The idea of the company
stems from the goal of trying to improve
the proteostasis milieu of the cell by
modulating key pathways. In the area of
neurodegenerative or protein misfolding
diseases in particular, interfering with
disease-modulating pathways is the ther-
apeutic focus.Reinhart estimates that the proteostasis
network consists of a collection of 1000–
1500 key proteins organized into 10–12
pathways. Each pathway contains about
50–200 proteins. ‘‘There are not an infinite
number of pathways,’’ says Reinhart,
‘‘and they are all connected and have
a lot of crosstalk between them.’’ Further,
the proteinswithin a pathway are highly in-
terconnected, forming protein/protein
interactions. Modulating one protein or
one pathway has flow-on effects onto
other pathways. ‘‘That is part of the reason
for thinking of this overall group of proteins
as a network, the proteostasis network
that maintains the remainder of the
proteome under constantly changing
conditions.’’
The proteostasis network pathways
have a common objective: keeping all ofthe proteins in a cell folded appropriately
and trafficked to the appropriate place,
which is accomplished by balancing
protein production and degradation. Yet
this system does not have a lot of reserve
capacity. If the system is stressed, even
a little bit, either in the context of environ-
mental stress or genetic stress in the form
of mutations, these stresses can very
quickly overcomes the reserve capacity
of the cell. Explains Reinhart, ‘‘The conse-
quences include the buildup of misfolded
proteins that then can form aggregates
that then go on to form a number of the
most significant diseases that we are
dealing with in this generation.’’ These
include protein and aggregation disor-
ders, like AD, PD, and Huntington’s
diseases (HD). Maintaining proteostasis
is also related to misfolding and mistraf-
ficking disorders, including the 50+ lyso-
somal storage diseases. It also includes
CF, which results when the cystic fibrosis
transmembrane conductance regulator
(CFTR) protein misfolds in the endo-
plasmic reticulum and is degradedChemistry & Biology 17, November 24, 2010 ªinstead of making it out to the surface of
the airway cells.
‘‘We may not know exactly what
contributes to the etiology of AD, for
example, but if we can modulate
a pathway that improves the cell’s capa-
bility to remove toxic aggregates, such
as the hyperphosporylated t protein or
soluble amyloid b oligomers, even in the
absence of knowing how they are gener-
ated and their precise mechanism of
cytotoxicity, we think we can produce
a beneficial therapeutic outcome,’’ says
Reinhart. This approach is in contrast to
much of the Alzheimer’s therapeutic strat-
egies that have gone into investigating
inhibitors of the enzymes involved in
creating these toxic entities, such as
b secretase inhibitors, g secretase inhibi-
tors, or antibodies that mop up toxic
amyloid b molecules.
Though they are not divulging the
precise pathways under study, PTI is
honing in on several groups of proteins
and associated pathways. Stress-
responsive signaling pathways are the
means by which cells constantly monitor
the integrity of protein homeostasis in
a given organelle or subcellular compart-
ment and then respond accordingly.
These pathways include the heat-shock
response, the unfolded protein response,
and the mitochondrial unfolded protein
response, all signaling cascades that
work similarly to adjust proteostasis
network capacity with demand. For
example, when the heat-shock response
is activated, several hundred members
of the proteostasis network increase in
concentration.
Other pathways involve chaperone
protein- and enzyme-mediated path-
ways; they help proteins fold and traffic
appropriately while degrading terminally
misfolded proteins. Some of these path-
ways are enhanced by the unfolded
protein response. Activation of protein
degradation pathways, such as autoph-
agy or modulation of the proteasome,
are also high on PTI’s list, especially for
aggregation-associated degenerative di-
seases. ‘‘We are focusing on pathways2010 Elsevier Ltd All rights reserved 1163
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says Reinhart. ‘‘By shepherding proteins
through various stages, either getting
rid of them when they are misfolded or
trafficking them more appropriately
when they are stuck in an organelle
(such as in CF), we hope to achieve
a beneficial outcome in the context of
the disease.’’
Scientific Founders
The core science behind PTI came from
the labs of its three scientific founders:
Jeffery Kelly (Scripps Research Institute),
Andrew Dillin (Salk Institute), and Ri-
chard Morimoto (Northwestern Univer-
sity). In 2000, when Kelly starting hearing
other researchers talk about overex-
pressing individual chaperone proteins
as an approach to fix a given misfolding
or aggregation-prone protein, he remem-
bered thinking this approach would be
less efficient or fail because chaperones
work as part of a complex system. ‘‘If
you do not embrace the system, you
are unlikely to be successful,’’ he says.
Over the next 5 years, Kelly invested in
learning more about the proteostasis
network. He and his colleagues did
their first technology-enabling experi-
ments in the early 2000s, which led to
the proof of principle that a small mole-
cule could be useful to restore protein
homeostasis.
‘‘The trick is to match proteostasis
network capacity with demand,’’ says
Kelly. ‘‘And if you have a system that can
do that, you can fix a misfolding-prone
protein, for example, and render the
protein functional.’’
Kelly says there is mounting evidence
that the inability to effectively signal
through stress-responsive signaling path-
ways could play a role in neurodegenera-
tive diseases. In animal models of these
diseases, as the animals age, their ability
to match healthy protein capacity with
demands diminishes. ‘‘The feeling is that
even though this is true at the cell or
organism level, you can still activate those
pathways chemically,’’ adds Kelly.1164 Chemistry & Biology 17, November 24,In the context of Alzheimer’s disease,
where the aggregation of the amyloid
b peptide is linked to neurodegeneration,
the Dillin and Kelly labs have shown that
when heat-shock response signaling is
activated, the pathological phenotype is
reduced in both C. elegans and mouse
models. Rick Morimoto’s lab showed
the same result in HD. Intriguingly,
though the plaque numbers increase,
the Alzheimer’s animals show less
neuronal loss and less behavioral and
memory deficiencies. ‘‘We argue that
plaque formation is a response of the
organism to protect itself,’’ says Kelly.
‘‘This is just some of the evidence that
one can manipulate the networks and
at least delay, if not prevent, neurode-
generation,’’ says Kelly, who explains
that animals treated in this way live
a normal life span.
PTI set up operations approximately
18 months ago, backed by $45 million
in venture capital funding. Though not
necessarily restricting itself to small
molecules, the company has put a lot
of effort into discovering small molecules
that activate a particular protein homeo-
stasis network pathway deficient in
a given disease. Today, its strategy is
to connect small molecules to pathways
that are known to remedy either misfold-
ing diseases (associated with protein
loss of function) or aggregation diseases
(associated with protein degradation and
gain of toxic function). ‘‘We very much
want to understand what components
of the protein homeostasis are the best
to target for each disease type,’’ adds
Kelly.
If this idea sounds vaguely familiar, but
in another context, there is good reason:
Kellywasa cofounder of FoldRx, a biotech
company focusing on developing thera-
pies for protein misfolding disorders,
which was acquired by Pfizer in October
2010. Amicus Therapeutics, based in
Cranbury, NJ, is also in the race to
develop small molecule mutant enzyme
stabilizers for specific lysosomal storage
disorders.2010 ª2010 Elsevier Ltd All rights reservedSmall Molecules as Proteostasis
Modulators
PTI has built itself up as an entity that can
test the concept of proteostasis modula-
tors. The company is using its capabilities
in transcriptional, proteomic, and func-
tional profiling to probe the proteostasis
network in human diseases. ‘‘The goal of
all of this work is to increase the health
span, the number of years we are
healthy,’’ says Kelly.
To date, PTI’s scientists havecompleted
two high throughput screens totaling
1.25 million compounds to identify new
chemical series. The company’s chemistry
group optimizes the chemistry and does
standard medicinal chemistry. ‘‘The only
difference being that the optimization
is done to optimize the state of the
networkmodulation,asopposedtoasingle
IC50 value, which is the way most large
pharma optimizes chemistry,’’ says Rein-
hart. PTI’s functional biology group tracks
functional efficacy in disease-relevant
cell-based models and in human samples;
its pharmacology group follows efficacy in
animal-based models.
Though a human clinical trial of any new
chemical compound is at least 2 years off,
PTI eventually hopes to bring benefit to
the larger neurodegenerative diseases
like AD and PD. They are also honing in
on retinal diseases, in particular diabetic
retinopathy, and smaller orphan diseases.
‘‘We are looking at controlling pro-
teome function much in the same way
enzyme inhibitors have been used histor-
ically,’’ says Kelly. In some diseases, less
protein or less active protein is the goal;
for example, matrix metalloproteases are
linked with cancer. Kelly theorizes cancer
and other diseases could be helped by
lowering protein-folding efficiency.
‘‘Beyond misfolding and degenerative
diseases, there is a much bigger picture
in terms of controlling proteome func-
tion.’’ PTI is out in front to ultimately prove
that concept in the clinic.Alice McCarthy (glodog@comcast.net) is a science
writer based in Gloucester, Massachusetts.
